2023
Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia
Huntington S, de Nigris E, Puckett J, Kamal-Bahl S, Farooqui M, Ryland K, Sarpong E, Leng S, Yang X, Doshi J. Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia. Leukemia & Lymphoma 2023, 64: 2286-2295. PMID: 37870435, DOI: 10.1080/10428194.2023.2256911.Peer-Reviewed Original ResearchConceptsChronic lymphocytic leukemiaIbrutinib discontinuationLymphocytic leukemiaHalf of patientsMonths of initiationElderly Medicare beneficiariesLarge unmet needPart D low-income subsidyLow-income subsidyCardiovascular comorbiditiesElderly patientsReal-world practiceIbrutinib treatmentLymphocytic lymphomaAdvanced ageClinical trialsMedical CenterMedicare claimsDiscontinuationHigh riskMedicare beneficiariesUnmet needPatientsLeukemiaTwo-thirdsCost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
Potnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Advances 2023, 7: 801-810. PMID: 36342852, PMCID: PMC10011202, DOI: 10.1182/bloodadvances.2022008097.Peer-Reviewed Original ResearchConceptsCAR T-cell therapyT-cell therapyQuality-adjusted life yearsIncremental cost-effectiveness ratioCAR T cellsChimeric antigen receptor T-cell therapySOC therapyFollicular lymphomaT cellsLife yearsR FLRefractory follicular lymphomaT cell strategiesThird-line settingLines of therapyIncremental clinical benefitUS payer perspectiveCost-effectiveness ratioTherapy remissionUnselected patientsCare therapyClinical benefitClinical trialsTreatment strategiesPayer perspective
2020
Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients
Di M, Huntington SF, Olszewski AJ. Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients. The Oncologist 2020, 26: 120-132. PMID: 33230948, PMCID: PMC7873335, DOI: 10.1002/onco.13610.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaChimeric antigen receptor T-cell therapyB-cell lymphomaChemotherapy-free approachProphylactic growth factorsOlder patientsStem cell transplantationT-cell therapyClinical trialsGeriatric vulnerabilitiesRefractory settingGeriatric assessmentCell transplantationPalliative careStandard first-line treatmentGrowth factorEarly palliative careFit older patientsTolerance of treatmentUnfavorable biologic featuresUnnecessary dose reductionsFirst-line settingFirst-line treatmentFavorable toxicity profile
2019
Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†
Davidoff AJ, Hu X, Bewersdorf JP, Wang R, Podoltsev NA, Huntington SF, Gore SD, Ma X, Zeidan AM. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†. Leukemia & Lymphoma 2019, 61: 1178-1187. PMID: 31878809, PMCID: PMC7735409, DOI: 10.1080/10428194.2019.1703970.Peer-Reviewed Original ResearchConceptsHigh-risk myelodysplastic syndromeExcess blastsRefractory anemiaOverall survival benefitRetrospective cohort studyMedian OSOS benefitRAEB patientsCohort studySurvival benefitTherapy useMyelodysplastic syndromeClinical trialsLower riskMedicare dataPatientsPropensity scoreOlder adultsDiagnosisAnemiaQuartileUnited StatesAssociationEnd resultOSCure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment.
Huntington SF. Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment. Hematology 2019, 2019: 252-259. PMID: 31808838, PMCID: PMC6913455, DOI: 10.1182/hematology.2019000030.Peer-Reviewed Original ResearchConceptsFirst-line treatmentClassic Hodgkin lymphomaBrentuximab vedotinNovel therapiesLarge-scale clinical trialsLarge randomized trialsHodgkin lymphoma treatmentRisk of progressionStandard cytotoxic therapiesChemotherapy cyclesDurable remissionsMultiagent chemotherapyMost patientsClinical outcomesRandomized trialsMedical oncologyCytotoxic therapyHodgkin's lymphomaLymphoma treatmentClinical trialsSelect populationIncomplete responseAlkylator chemotherapyChemotherapyAdvanced stageEvaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials
Giri S, Aryal M, Yu H, Grimshaw A, Pathak R, Huntington S, Dhakal B. Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials. Blood 2019, 134: 2188. DOI: 10.1182/blood-2019-130389.Peer-Reviewed Original ResearchProgression-free survivalOverall response rateHematopoietic cell transplantFront-line treatmentAdverse eventsOverall survivalMM patientsMultiple myelomaFrontline regimensClinical trialsAdvisory CommitteeCommon grade 3Cumulative ranking (SUCRA) probabilitiesFront-line regimensHigher adverse eventsPrimary efficacy outcomeTransplant-ineligible patientsPhase III RCTsNetwork Meta-AnalysisBias assessment toolRisk of biasEvaluation of efficacyIndividual patient needsEfficacious regimenEfficacious regimensUtilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States
Huntington S, Soulos P, Barr P, Jacobs R, Lansigan F, Odejide O, Schwartzberg L, Davidoff A, Gross C. Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States. Blood 2019, 134: 797. DOI: 10.1182/blood-2019-122054.Peer-Reviewed Original ResearchFirst-line settingChronic lymphocytic leukemiaFlatiron Health databaseECOG performance statusFirst-line treatmentEarly discontinuationMultivariable logistic regressionPerformance statusIbrutinib discontinuationSpeakers bureauClinical trialsCLL diagnosisCLL therapyLymphocytic leukemiaHealth databasesLogistic regressionBruton tyrosine kinase inhibitorsFirst-line ibrutinibUse of ibrutinibWorse performance statusPoor performance statusRetrospective cohort studyCommunity oncology settingClinical decision support toolCommunity oncology practicesAssociation of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia & Lymphoma 2019, 61: 397-408. PMID: 31570040, PMCID: PMC7732188, DOI: 10.1080/10428194.2019.1663423.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeOverall survivalHMA cyclesHMA therapyProvider experienceCox proportional hazards modelOlder MDS patientsMedian overall survivalPercent of patientsSEER-Medicare dataMultivariate logistic regressionProportional hazards modelHMA initiationClinical outcomesMDS patientsClinical trialsMedian numberHMA treatmentHazards modelPatientsSignificant associationLogistic regressionPopulation-level survivalSurvivalSyndrome
2018
Outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective Analysis
Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, Huntington SF, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J. Outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective Analysis. The Oncologist 2018, 24: 955-962. PMID: 30568021, PMCID: PMC6656463, DOI: 10.1634/theoncologist.2018-0538.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenal Cortex HormonesAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalDrug-Related Side Effects and Adverse ReactionsFemaleFollow-Up StudiesHodgkin DiseaseHumansMaleMiddle AgedNivolumabPrognosisProgrammed Cell Death 1 ReceptorRetrospective StudiesSurvival RateYoung AdultConceptsProgression-free survivalClassical Hodgkin lymphomaPD-1 inhibitorsPD-1iPercent of patientsOverall response rateComplete responseResponse rateSystemic chemotherapyOverall survivalPartial responseSystemic therapyCHL patientsHodgkin's lymphomaClinical trialsRetrospective analysisToxicity profileReal-world settingDeath-1 inhibitor nivolumabMedian progression-free survivalR cHLRefractory classical Hodgkin lymphomaDeath-1 inhibitorsPrior autoimmune diseaseR cHL patientsPhase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality
Huntington S, Schuster S, He W, Shen T, Walker H, Leary L, Boyhen K, Gill J, Chatburn E, Kennard K, Nasta S, Landsburg D, Porter D, Napier E, Hughes M, Latorre T, Walsh K, Dorsey C, Svoboda J, Addis V, Anderson B, Leblond E, Song Y, Zhu J, Deng L, Brander D, Ding W, Rosenthal A, Tun H, Mato A. Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality. Blood 2018, 132: 5384. DOI: 10.1182/blood-2018-99-112944.Peer-Reviewed Original ResearchClassical Hodgkin lymphomaChronic lymphocytic leukemiaMantle cell lymphomaRefractory lymphoma patientsLow-dose combinationClinical trialsAdverse eventsFollicular lymphomaCancer HospitalLymphoma patientsStudy treatmentCell lymphomaDose combinationDose-limiting toxicity periodRefractory chronic lymphocytic leukemiaPeking University Cancer HospitalAdvisory CommitteeLarge B-cell lymphomaPhase Ia studyECOG performance statusSubsequent treatment cyclesBeijing Cancer HospitalMechanism-based combinationsB-cell lymphomaNovartis Pharmaceuticals Corporation
2016
Characterization of Real World Survival Outcomes Among Older Adults with Chronic Lymphocytic Leukemia Receiving Second Line Treatment in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database
Mato A, Jahnke J, Li P, Mehra M, Ladage V, Mahler M, Fanning M, Doshi J, Huntington S. Characterization of Real World Survival Outcomes Among Older Adults with Chronic Lymphocytic Leukemia Receiving Second Line Treatment in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database. Blood 2016, 128: 4790. DOI: 10.1182/blood.v128.22.4790.4790.Peer-Reviewed Original ResearchSecond-line treatmentChronic lymphocytic leukemiaSecond-line cohortSecond-line therapyOverall survivalLine treatmentInitial therapyClinical trialsLine therapyInitial treatmentCLL treatmentSurvival outcomesCLL patientsOlder adultsNovel agentsCLL outcomeLymphocytic leukemiaMedicare feeCommon second-line treatmentReal-world survival outcomesRecent landmark clinical trialsRelapsed chronic lymphocytic leukemiaMultivariate Cox regression modelingSecond lineAdvisory CommitteeCharacterization of Real World Treatment Patterns and Outcomes Among Older Adults with Chronic Lymphocytic Leukemia in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database
Mato A, Jahnke J, Li P, Mehra M, Ladage V, Mahler M, Huntington S, Doshi J. Characterization of Real World Treatment Patterns and Outcomes Among Older Adults with Chronic Lymphocytic Leukemia in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database. Blood 2016, 128: 4773. DOI: 10.1182/blood.v128.22.4773.4773.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaOlder CLL patientsOverall survivalTreatment initiationCox regressionCLL patientsClinical trialsFirst treatmentNovel agentsChlorambucil monotherapyOlder adultsLymphocytic leukemiaMedicare feeClinical practiceLow-income subsidy statusReal-world treatment patternsRecent landmark clinical trialsCLL/SLL patientsLogistic regressionOlder individualsAdvisory CommitteeGilead SciencesReal-world outcome dataAnemia/thrombocytopeniaApproval of ibrutinibComparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. British Journal Of Haematology 2016, 175: 829-840. PMID: 27650975, DOI: 10.1111/bjh.14305.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeRAEB patientsMedian survivalClinical trialsMultivariate Cox proportional hazards modelCox proportional hazards modelKaplan-Meier methodPopulation-based survivalSignificant survival differenceComparative clinical effectivenessProportional hazards modelAgent azacitidineHMA initiationExcess blastsOlder patientsRandomized trialsHistological subtypesRefractory anemiaClinical effectivenessSurvival differencesSubset analysisSurvival advantageHazards modelPatientsDecitabine
2015
Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Zeidan A, Long J, Hall J, Wang R, Huntington S, Abel G, Prebet T, Podoltsev N, Gross C, Gore S, Ma X, Davidoff A. Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS). Blood 2015, 126: 3285. DOI: 10.1182/blood.v126.23.3285.3285.Peer-Reviewed Original ResearchHigh-risk myelodysplastic syndromeHR-MDS patientsKaplan-Meier survival curvesEnd of studyHMA initiationMedian OSClinical trialsComorbidity countHazard ratioHigh school educationClinical practiceMultivariate Cox proportional hazards modelSurvival curvesEnd Results-Medicare databaseMedian household incomeRandomized phase III trialReal-world clinical practiceCox proportional hazards modelOlder MDS patientsDisability Status ScoreRetrospective cohort studyOverall survival advantagePhase III trialsYear of diagnosisErythropoiesis-stimulating agents